A5000996802- Pharmacological Effects and Toxicity Studies
- Hemoglobinopathies and Related Disorders
- Drug Transport and Resistance Mechanisms
- Muscle and Compartmental Disorders
- Iron Metabolism and Disorders
- Graphene and Nanomaterials Applications
- Membrane-based Ion Separation Techniques
- RNA modifications and cancer
- Electrospun Nanofibers in Biomedical Applications
- Nanoparticle-Based Drug Delivery
- Poisoning and overdose treatments
- Abdominal Surgery and Complications
- Trace Elements in Health
- Acute Kidney Injury Research
- Anesthesia and Neurotoxicity Research
- Carbon and Quantum Dots Applications
- Heme Oxygenase-1 and Carbon Monoxide
University of Massachusetts Lowell
2021-2025
Gordon Center for Medical Imaging
2023
Harvard University
2023
Massachusetts General Hospital
2023
Deferoxamine (DFO) is an FDA-approved iron-chelating agent which shows good therapeutic efficacy, however, its short blood half-life presents challenges such as the need for repeated injections or continuous infusions. Considering lifelong of chelating agents iron overload patients, a sustained-release formulation that can reduce number chelator administrations essential. Here, injectable hydrogel formulations prepared by integrating crosslinked hyaluronic acid into Pluronic F127 extended...
Acute kidney injury (AKI) increases the risk of in-hospital death, adds to expense care, and early chronic disease. AKI often follows an acute event such that timely treatment could ameliorate potentially reduce additional Despite therapeutic success dexamethasone in animal models, clinical trials have not demonstrated broad success. To improve safety efficacy for AKI, we developed characterized a novel, kidney-specific nanoparticle enabling specific within-kidney targeting proximal tubular...
Platinum-based anticancer agents have revolutionized oncological treatments globally. However, their therapeutic efficacy is often accompanied by systemic toxicity. Carboplatin, recognized for its relatively lower toxicity profile than cisplatin, still presents off-target toxicities, including dose-dependent cardiotoxicity, neurotoxicity, and myelosuppression. In this study, we demonstrate a delivery strategy of carboplatin to mitigate leveraging the potential zwitterionic nanocarrier,...
Deferoxamine (DFO) is an effective FDA-approved iron chelator. However, its use considerably limited by off-target toxicities and extremely cumbersome dose regimen with daily infusions. The recent development of a deferoxamine-based nanochelator (DFO-NP) selective renal excretion has shown promise in ameliorating animal models overload substantially improved safety profile. To further the preclinical this promising to inform on feasibility clinical development, it necessary fully...
Aim: To characterize the pharmacokinetics of deferoxamine-conjugated nanoparticles (DFO-NPs), a novel nanochelator for removing excess iron. Materials & methods: The DFO-NPs were evaluated in Sprague-Dawley rats at three doses (3.3, 10 and 30 μmol/kg) after intravenous subcutaneous administration. Results: exhibited biphasic concentration-time profile administration with short terminal half-life (2.0-3.2 h), dose-dependent clearance (0.111-0.179 l/h/kg), minimal tissue distribution exclusive...
Deferoxamine (DFO) is an effective FDA-approved iron chelator; however, its use considerably limited by off-target toxicities and extremely cumbersome dose regimen involving daily infusions. The recent development of a deferoxamine-based nanochelator (DFO-NP) with selective renal excretion has shown promise in ameliorating overload associated physiological complications rodent models substantially improved safety profile. While the dose- administration route-dependent pharmacokinetics (PK)...